The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

Rapid Growth Trajectory

• The antisense & RNAi therapeutics market size has surged in recent years.
• From $1.59 billion in 2023 to $1.77 billion in 2024, it boasts a Compound Annual Growth Rate (CAGR) of 11.4%.
• Growth in the historic period attributed to:
  • Rise in funding.
  • Advancement in technologies.
  • Increase in healthcare expenditure.
  • Rapid growth in elderly population.
  • Economic growth in emerging markets.

Future Projections

• Antisense & RNAi therapeutics market projected to reach $2.81 billion in 2028.
• CAGR expected to rise to 12.3%.
• Forecast period growth attributed to:
  • Increased healthcare access.
  • Rising prevalence of cancer.
  • COVID-19’s impact, increasing demand for antisense and RNAi therapeutics.

Read More On The Antisense & RNAi Therapeutics Market Report 2024 – https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

Emerging Demand for Neurodegenerative Disorders & Infectious Diseases

• Rise in coronary artery diseases, neurodegenerative disorders, and infectious diseases contribute to demand.
• Gene suppression approaches utilized for treatment.
• Alzheimer’s disease and Parkinson’s disease most prevalent neurodegenerative diseases globally.
• Growing prevalence expected to drive market growth.

Major Players in the Market

• Companies contributing to the market’s growth include:
  • Biogen Inc.
  • Ionis Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals Inc.
  • Arrowhead Pharmaceuticals Inc.
  • Moderna Inc.
  • Sanofi S.A.
  • And many more…

Strategic Collaborations Driving Innovation

• Major companies engage in partnerships to sustain competitiveness.
• Collaborations aimed at achieving common goals.
• Example: Orbit Discovery Limited partnered with SanegeneBio Inc. for RNA therapeutics development.
• Collaboration between AstraZeneca PLC and Ionis Pharmaceuticals Inc. for Eplontersen development.

Market Segmentation

• Segmented by:
  1. Technology: RNA Interference, Antisense RNA
  2. Route of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
  3. Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

Regional Dominance

• North America led the antisense & RNAi therapeutics market in 2023.

The antisense & RNAi therapeutics market presents a promising landscape for innovation and growth. With strategic collaborations, technological advancements, and rising healthcare demands, this sector is poised for continued expansion. As research and development efforts intensify, addressing critical medical needs like neurodegenerative disorders and infectious diseases, the market is set to fulfill its potential, providing novel solutions for global health challenges.

Request for A Sample Of The Global Antisense & RNAi Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=3389&type=smp